Design Therapeutics (DSGN) Other Operating Expenses (2025)

Design Therapeutics (DSGN) reported Other Operating Expenses of $59.0 million for Q4 2025, up 1166.17% sequentially from $4.7 million in Q3 2025.

Design Therapeutics (DSGN) Other Operating Expenses (2025) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of Other Operating Expenses data on file, last reported at $59.0 million in Q4 2025.

For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to $59.0 million; the trailing twelve-month figure through Mar 2026 stood at $63.7 million (changed N/A YoY), and the FY2025 full-year result was $59.0 million, changed N/A from the prior year.
Other Operating Expenses grew to $59.0 million in Q4 2025, from $4.7 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $59.0 million in Q4 2025 to a low of $4.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Design Therapeutics	714.48 Mn	491.66 Mn	-

Download Data

Date	Value
Dec 31, 2025	59.03 Mn
Sep 30, 2025	4.66 Mn